Logo image of ELVN

ENLIVEN THERAPEUTICS INC (ELVN) Stock Fundamental Analysis

NASDAQ:ELVN - Nasdaq - US29337E1029 - Common Stock - Currency: USD

21.8  +0.33 (+1.54%)

After market: 21.8 0 (0%)

Fundamental Rating

3

Taking everything into account, ELVN scores 3 out of 10 in our fundamental rating. ELVN was compared to 193 industry peers in the Pharmaceuticals industry. While ELVN has a great health rating, there are worries on its profitability. ELVN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELVN had negative earnings in the past year.
In the past year ELVN has reported a negative cash flow from operations.
ELVN had negative earnings in 4 of the past 5 years.
ELVN had a negative operating cash flow in each of the past 5 years.
ELVN Yearly Net Income VS EBIT VS OCF VS FCFELVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M

1.2 Ratios

ELVN has a Return On Assets (-27.90%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -29.55%, ELVN is doing good in the industry, outperforming 65.76% of the companies in the same industry.
Industry RankSector Rank
ROA -27.9%
ROE -29.55%
ROIC N/A
ROA(3y)-26.47%
ROA(5y)-40.81%
ROE(3y)-28.93%
ROE(5y)-45.24%
ROIC(3y)N/A
ROIC(5y)N/A
ELVN Yearly ROA, ROE, ROICELVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

ELVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELVN Yearly Profit, Operating, Gross MarginsELVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ELVN has been increased compared to 1 year ago.
ELVN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ELVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ELVN Yearly Shares OutstandingELVN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ELVN Yearly Total Debt VS Total AssetsELVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 36.54 indicates that ELVN is not in any danger for bankruptcy at the moment.
The Altman-Z score of ELVN (36.54) is better than 96.20% of its industry peers.
ELVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 36.54
ROIC/WACCN/A
WACCN/A
ELVN Yearly LT Debt VS Equity VS FCFELVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 17.44 indicates that ELVN has no problem at all paying its short term obligations.
ELVN's Current ratio of 17.44 is amongst the best of the industry. ELVN outperforms 89.67% of its industry peers.
A Quick Ratio of 17.44 indicates that ELVN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 17.44, ELVN belongs to the top of the industry, outperforming 89.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.44
Quick Ratio 17.44
ELVN Yearly Current Assets VS Current LiabilitesELVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ELVN have decreased strongly by -161.28% in the last year.
EPS 1Y (TTM)-161.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ELVN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.27% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y9.24%
EPS Next 2Y-4.62%
EPS Next 3Y-7.7%
EPS Next 5Y-10.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELVN Yearly Revenue VS EstimatesELVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ELVN Yearly EPS VS EstimatesELVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ELVN. In the last year negative earnings were reported.
Also next year ELVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELVN Price Earnings VS Forward Price EarningsELVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELVN Per share dataELVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

ELVN's earnings are expected to decrease with -7.70% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.62%
EPS Next 3Y-7.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENLIVEN THERAPEUTICS INC

NASDAQ:ELVN (2/21/2025, 8:15:37 PM)

After market: 21.8 0 (0%)

21.8

+0.33 (+1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners85.96%
Inst Owner Change-98.54%
Ins Owners5.62%
Ins Owner Change-2.57%
Market Cap1.07B
Analysts85.71
Price Target38.61 (77.11%)
Short Float %18.88%
Short Ratio31.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.15%
Min EPS beat(2)5.29%
Max EPS beat(2)27.01%
EPS beat(4)4
Avg EPS beat(4)13.43%
Min EPS beat(4)5.29%
Max EPS beat(4)27.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.86%
EPS NQ rev (1m)1.09%
EPS NQ rev (3m)2.69%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.69
P/tB 3.69
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.4
OCFYN/A
SpS0
BVpS5.9
TBVpS5.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.9%
ROE -29.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.47%
ROA(5y)-40.81%
ROE(3y)-28.93%
ROE(5y)-45.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.44
Quick Ratio 17.44
Altman-Z 36.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.73%
Cap/Depr(5y)121.17%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-161.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
EPS Next Y9.24%
EPS Next 2Y-4.62%
EPS Next 3Y-7.7%
EPS Next 5Y-10.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-56.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.04%
EBIT Next 3Y-33.64%
EBIT Next 5YN/A
FCF growth 1Y-85.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-88.05%
OCF growth 3YN/A
OCF growth 5YN/A